Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) major shareholder Morningside Venture Investment sold 50,000 shares of the firm's stock in a transaction on Wednesday, January 25th. The stock was sold at an average price of $6.85, for a total value of $342,500.00. Following the transaction, the insider now owns 5,662,993 shares in the company, valued at $38,791,502.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Morningside Venture Investment also recently made the following trade(s):
Get
Kezar Life Sciences alerts:
- On Monday, January 23rd, Morningside Venture Investment sold 80,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.81, for a total value of $544,800.00.
- On Tuesday, January 17th, Morningside Venture Investment sold 6,114 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.79, for a total value of $41,514.06.
- On Thursday, January 12th, Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.77, for a total value of $33,850.00.
- On Thursday, January 5th, Morningside Venture Investment sold 12,162 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.97, for a total value of $84,769.14.
Kezar Life Sciences Stock Performance
KZR stock opened at $6.90 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 31.15 and a current ratio of 31.15. The stock has a market capitalization of $471.82 million, a price-to-earnings ratio of -6.83 and a beta of 0.23. Kezar Life Sciences, Inc. has a 1 year low of $4.30 and a 1 year high of $18.55. The stock's fifty day moving average is $6.98 and its two-hundred day moving average is $8.24.
Kezar Life Sciences (NASDAQ:KZR – Get Rating) last posted its earnings results on Thursday, November 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.01. On average, research analysts predict that Kezar Life Sciences, Inc. will post -1.03 EPS for the current year.
Institutional Investors Weigh In On Kezar Life Sciences
Hedge funds and other institutional investors have recently modified their holdings of the stock. Great West Life Assurance Co. Can bought a new stake in shares of Kezar Life Sciences during the third quarter valued at about $26,000. Tower Research Capital LLC TRC raised its stake in shares of Kezar Life Sciences by 88.9% during the third quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company's stock valued at $58,000 after purchasing an additional 3,190 shares in the last quarter. Robeco Institutional Asset Management B.V. bought a new stake in shares of Kezar Life Sciences during the third quarter valued at about $68,000. Amalgamated Bank bought a new stake in shares of Kezar Life Sciences during the first quarter valued at about $70,000. Finally, UBS Asset Management Americas Inc. bought a new stake in shares of Kezar Life Sciences during the third quarter valued at about $86,000. 84.03% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Wells Fargo & Company cut their target price on Kezar Life Sciences from $17.00 to $14.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 3rd.
Kezar Life Sciences Company Profile
(Get Rating)
Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.
Featured Stories
- Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
